UPDATE: Canaccord Genuity Reiterates Buy Rating, Raises PT on TearLab Corporation
In a report published Monday, Canaccord Genuity reiterated its Buy rating on TearLab Corporation (NASDAQ: TEAR), and raised its price target from $6.00 to $8.00.
Canaccord Genuity noted, “Given strong underlying business trends, we increase our price target to $8 from $6 as we believe the growth profile of the stock justifies a higher multiple. In our opinion, TEAR should start benefitting from physician referrals (>500 IB), expanding sales force (12 reps and four managers), and robust lead activity from AAO conference.”
TearLab Corporation closed on Friday at $5.31.
Latest Ratings for TEAR
|Aug 2016||Roth Capital||Downgrades||Buy||Neutral|
|Jul 2016||Rodman & Renshaw||Initiates Coverage on||Buy|
|May 2016||Feltl & Co.||Upgrades||Buy||Strong Buy|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.